Entos Pharmaceuticals (Entos), a biotechnology company developing genetic medicines with its Fusogenix nucleic acid delivery platform, is excited to work with Alberta Cell Therapy Manufacturing and The Ottawa Hospital’s Biotherapeutics Manufacturing Centre to manufacture and ready doses of Entos’ made-in-Canada Covigenix VAX-001 vaccine for upcoming clinical trials at the Canadian Centre for Vaccinology.
About Alberta Cell Therapy Manufacturing
Located at the University of Alberta, ACTM offers a range of integrated services from technology transfer, process and assay development through to GMP manufacturing of products for clinical trials. The ACTM’s Scientific Director Dr. Greg Korbutt and ACTM Manager Gayle Piat are excited to support the production of Ento’s vaccine. With state-of-the-art equipment, a 10,000 square foot cleanroom facility and expert GMP staff, ACTM is ideally positioned to deliver biotherapeutic manufacturing services in Canada. The addition of a fill-finish suite is currently underway and will be operational in 2021. Visit www.ualberta.ca/actm.
Keep reading here.